Research programme: anti-hFcRn mAbs - HanAll BioPharma

Drug Profile

Research programme: anti-hFcRn mAbs - HanAll BioPharma

Alternative Names: HanAll's anti-hFcRn mAbs; HL-161

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HanAll Biopharma
  • Class Monoclonal antibodies
  • Mechanism of Action Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Lupus nephritis; Myasthenia gravis; Neuromyelitis optica; Pemphigus

Most Recent Events

  • 12 Sep 2017 HL161 licensed to Harbour BioMed in in Greater China, including Hong Kong, Macau and Taiwan
  • 12 Sep 2017 HanAll BioPharma plans a phase I clinical trial for a subcutaneous injectable formulation of HL-161 by the end of 2017
  • 14 Aug 2015 HL 161 is available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top